TL;DR
Topical tranexamic acid moves melasma slower than oral but with almost none of the systemic risk. At 60 days, a 3 to 5 percent topical shifts MASI scores by 20 to 35 percent when paired with sun avoidance. Without it, the number drops by half. The biggest variable is not the molecule, it is the SPF.
I followed two long-term melasma testers on 5 percent topical tranexamic acid through a full sixty days with weekly colourimetry readings. The takeaway changed how I think about the entire melasma stack: the topical is doing real work, but the discipline of the sun habit is doing more.
How tranexamic acid works on pigment
Tranexamic acid was developed as an antifibrinolytic for bleeding disorders. The pigment-fading effect was discovered accidentally when patients on oral tranexamic for menorrhagia reported their melasma lifted. The mechanism is interference with the plasminogen-plasmin system in melanocytes, which downregulates tyrosinase and reduces melanin production.
Topically, the same pathway is engaged but at much lower systemic exposure. Oral tranexamic has the higher efficacy curve and the higher risk profile (thrombosis is the rare but real adverse event). Topical tranexamic gives you most of the mechanism with almost none of the systemic risk. That trade-off is why I prefer the topical for most readers.
What 60 days looked like in tester skin
Tester A. Fitzpatrick IV, age 38, centro-facial melasma of approximately four years duration. Baseline MASI score 8.2. Sun avoidance discipline: high. SPF 50 daily, wide-brimmed hat outdoors, car window film installed. At day 60, MASI dropped to 5.7, a 30 percent reduction. The change was visible to her partner without prompting.
Tester B. Fitzpatrick III, age 34, malar melasma of approximately two years duration. Baseline MASI 6.5. Sun avoidance discipline: moderate. SPF 30 daily, no hat, no window film. At day 60, MASI dropped to 5.6, a 14 percent reduction. The change was barely visible.
Same molecule, same concentration, same compliance with the serum itself. Different SPF behaviour. Different outcome. Read our melasma routine for the full stack including sun discipline.
Why 60 days is the right checkpoint
Melanin transfer happens on a 28 to 40 day cycle. The pigment you see today was made weeks ago and has been working its way up through the epidermis. A topical that reduces new melanin production cannot reach pigment already deposited. It can only stop the next wave.
Sixty days catches one and a half pigment cycles, which is the first checkpoint where meaningful clinical change should be visible. Anything claimed before day 30 is mostly antioxidant glow or sun-avoidance reward, not pigment movement.
What happens past 60 days
The 90 to 180 day window is where topical tranexamic earns its keep. Most clinical trials show continued improvement out to 12 weeks and plateau between 16 and 24 weeks. Stopping at day 60 because results look modest is the most common mistake testers make. Our pigmentation timeline shows where the curve flattens.
Combining with the rest of the stack
Topical tranexamic is most effective in combination, not in isolation. The standard dermatology stack for melasma is tranexamic plus azelaic plus retinoid plus aggressive SPF, with hydroquinone added in severe cases for short courses.
The mistake I see most often is single-ingredient monotherapy. Melasma is a multi-pathway condition, and topicals that hit different parts of the pigment cascade produce better outcomes than maxing out one molecule. Our azelaic guide covers the partner ingredient most often paired with tranexamic.
The contrarian take
Topical tranexamic acid is sold as a melasma miracle, and it is not. It is a useful component of a melasma stack that requires discipline most people will not maintain. The brands selling it as a hero ingredient know that compliance with the rest of the stack (SPF, hat, behavioural sun avoidance) is the actual rate-limiting step, and they prefer the easier story of “this ingredient changes everything”. The ingredient does some of the work. Your behaviour does the rest.
Real numbers
A 2017 randomised double-blind split-face trial of 5 percent topical tranexamic acid versus 3 percent hydroquinone in 60 melasma patients (Banihashemi M et al., Journal of Cosmetic Dermatology) found no statistically significant difference between the two over 12 weeks, with both arms showing approximately 50 percent MASI reduction at week 12. At week 8 (close to our 60-day mark), the tranexamic arm showed approximately 31 percent MASI reduction, and the hydroquinone arm 34 percent. The side-effect profile was substantially better in the tranexamic arm.
FAQ
Should I take oral tranexamic instead? Discuss with a derm. Oral works better but has thrombosis risk. Topical is the safer starting point.
What concentration should I look for? 3 to 5 percent topical. Below 2 percent the data is thinner.
Can I combine it with vitamin C? Yes, vitamin C in the morning and tranexamic-containing serum in the evening (or both in either order; the conflict is overstated).
How do I know if it is working? Photograph in identical light weekly. Memory is not reliable for slow pigment change.
Is it safe in pregnancy? Topical exposure is low but evidence is limited. Most dermatologists pause it during pregnancy.
More slow-pigment content is in our melasma tag.
Sources
Banihashemi M et al. Comparison of topical tranexamic acid versus hydroquinone in melasma. Journal of Cosmetic Dermatology, 2017. JAAD review of tranexamic acid in dermatology, 2020. NIH on plasminogen-plasmin system in melanogenesis, 2016. AAD position on melasma management, 2022.